769 related articles for article (PubMed ID: 9361936)
1. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
[TBL] [Abstract][Full Text] [Related]
2. The impact of CMV prevention on long-term recipient and graft survival in heart transplant recipients: analysis of the Scientific Registry of Transplant Recipients (SRTR) database.
Snydman DR; Kistler KD; Ulsh P; Bergman GE; Vensak J; Morris J
Clin Transplant; 2011; 25(4):E455-62. PubMed ID: 21504474
[TBL] [Abstract][Full Text] [Related]
3. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.
Bonaros N; Mayer B; Schachner T; Laufer G; Kocher A
Clin Transplant; 2008; 22(1):89-97. PubMed ID: 18217909
[TBL] [Abstract][Full Text] [Related]
4. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
[TBL] [Abstract][Full Text] [Related]
5. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR
Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
[TBL] [Abstract][Full Text] [Related]
6. The association between cytomegalovirus immune globulin and long-term recipient and graft survival following liver transplantation.
Fisher RA; Kistler KD; Ulsh P; Bergman GE; Morris J
Transpl Infect Dis; 2012 Apr; 14(2):121-31. PubMed ID: 21883757
[TBL] [Abstract][Full Text] [Related]
7. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group.
Snydman DR; Werner BG; Dougherty NN; Griffith J; Rohrer RH; Freeman R; Jenkins R; Lewis WD; O'Rourke E
Transplant Proc; 1994 Oct; 26(5 Suppl 1):23-7. PubMed ID: 7940972
[No Abstract] [Full Text] [Related]
8. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial.
Snydman DR; Werner BG; Dougherty NN; Griffith J; Rubin RH; Dienstag JL; Rohrer RH; Freeman R; Jenkins R; Lewis WD; Hammer S; O'Rourke E; Grady GF; Fawaz K; Kaplan MM; Hoffman MA; Katz AT; Doran M;
Ann Intern Med; 1993 Nov; 119(10):984-91. PubMed ID: 8214995
[TBL] [Abstract][Full Text] [Related]
10. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?
Singh N; Wannstedt C; Keyes L; Wagener MM; Cacciarelli TV
Liver Transpl; 2005 Jun; 11(6):700-4. PubMed ID: 15915496
[TBL] [Abstract][Full Text] [Related]
11. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
Rosen HR; Shackleton CR; Higa L; Gralnek IM; Farmer DA; McDiarmid SV; Holt C; Lewin KJ; Busuttil RW; Martin P
Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061
[TBL] [Abstract][Full Text] [Related]
12. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.
George MJ; Snydman DR; Werner BG; Griffith J; Falagas ME; Dougherty NN; Rubin RH
Am J Med; 1997 Aug; 103(2):106-13. PubMed ID: 9274893
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus prevention and long-term recipient and graft survival in pediatric heart transplant recipients.
Snydman DR; Kistler KD; Ulsh P; Morris J
Transplantation; 2010 Dec; 90(12):1432-8. PubMed ID: 21076378
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
15. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
[TBL] [Abstract][Full Text] [Related]
17. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation.
McVicar JP; Kowdley KV; Emond MJ; Barr D; Marsh CL; Carithers RL; Perkins JD
Clin Transplant; 1997 Aug; 11(4):328-33. PubMed ID: 9267724
[TBL] [Abstract][Full Text] [Related]
18. Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival.
Abraham KA; O'Kelly P; Spencer S; Hickey DP; Conlon PJ; Walshe JJ
Ren Fail; 2008; 30(2):141-6. PubMed ID: 18300112
[TBL] [Abstract][Full Text] [Related]
19. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors.
Bajjoka I; Hsaiky L; Brown K; Abouljoud M
Liver Transpl; 2008 Jan; 14(1):66-72. PubMed ID: 18161842
[TBL] [Abstract][Full Text] [Related]
20. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients.
Snydman DR; Werner BG; Heinze-Lacey B; Berardi VP; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS
N Engl J Med; 1987 Oct; 317(17):1049-54. PubMed ID: 2821397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]